Loading...

Aptose Biosciences

DB:LTIA
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LTIA
DB
CA$99M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
  • Aptose Biosciences has significant price volatility in the past 3 months.
LTIA Share Price and Events
7 Day Returns
0.7%
DB:LTIA
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-45.4%
DB:LTIA
-10.2%
DE Biotechs
-6%
DE Market
LTIA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aptose Biosciences (LTIA) 0.7% -16.9% -16.9% -45.4% -28% -59.4%
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • LTIA underperformed the Biotechs industry which returned -10.2% over the past year.
  • LTIA underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
LTIA
Industry
5yr Volatility vs Market

Value

 Is Aptose Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Aptose Biosciences. This is due to cash flow or dividend data being unavailable. The share price is €1.595.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aptose Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aptose Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:LTIA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.86
TSX:APS Share Price ** TSX (2019-04-18) in CAD CA$2.45
TSX:APS Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.747 $1.83
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aptose Biosciences.

DB:LTIA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:APS Share Price ÷ EPS (both in USD)

= 1.83 ÷ -0.86

-2.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aptose Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Aptose Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Aptose Biosciences's expected growth come at a high price?
Raw Data
DB:LTIA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-11%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aptose Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aptose Biosciences's assets?
Raw Data
DB:LTIA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.37
TSX:APS Share Price * TSX (2019-04-18) in CAD CA$2.45
TSX:APS Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.747 $1.83
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:LTIA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:APS Share Price ÷ Book Value per Share (both in USD)

= 1.83 ÷ 0.37

4.96x

* Primary Listing of Aptose Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aptose Biosciences is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Aptose Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Aptose Biosciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Aptose Biosciences expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-11%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aptose Biosciences expected to grow at an attractive rate?
  • Unable to compare Aptose Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Aptose Biosciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Aptose Biosciences's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:LTIA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:LTIA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -11%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:LTIA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:LTIA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 68 -32 -35 3
2022-12-31 23 -36 -56 5
2021-12-31 4 -32 -39 5
2020-12-31 1 -36 -41 5
2019-12-31 0 -24 -29 6
DB:LTIA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -23 -29
2018-09-30 -21 -26
2018-06-30 -18 -23
2018-03-31 -12 -15
2017-12-31 -10 -12
2017-09-30 -10 -11
2017-06-30 -11 -12
2017-03-31 -12 -14
2016-12-31 -12 -14
2016-09-30 -12 -15
2016-06-30 -12 -14
2016-03-31 -12 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aptose Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Aptose Biosciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:LTIA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Aptose Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LTIA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.32 0.22 -0.63 3.00
2022-12-31 -0.75 0.02 -1.19 5.00
2021-12-31 -0.68 -0.54 -0.81 4.00
2020-12-31 -0.84 -0.72 -0.98 5.00
2019-12-31 -0.72 -0.69 -0.74 6.00
DB:LTIA Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.86
2018-09-30 -0.84
2018-06-30 -0.82
2018-03-31 -0.60
2017-12-31 -0.52
2017-09-30 -0.57
2017-06-30 -0.72
2017-03-31 -0.97
2016-12-31 -1.12
2016-09-30 -1.19
2016-06-30 -1.17
2016-03-31 -1.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aptose Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Aptose Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aptose Biosciences has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Aptose Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aptose Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aptose Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Aptose Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aptose Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Aptose Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aptose Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LTIA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -28.87 10.37 13.73
2018-09-30 -25.88 9.48 11.61
2018-06-30 -23.01 8.78 9.41
2018-03-31 -15.19 7.66 7.68
2017-12-31 -11.64 5.55 6.27
2017-09-30 -10.85 5.23 5.83
2017-06-30 -11.75 5.61 6.34
2017-03-31 -13.73 6.07 7.83
2016-12-31 -14.24 6.44 7.83
2016-09-30 -14.58 7.05 7.70
2016-06-30 -14.16 7.37 7.45
2016-03-31 -12.44 7.50 5.93
2016-01-01 -11.71 7.99 4.87
2015-09-30 -9.46 7.33 4.06
2014-12-31 -11.50 8.20 3.56
2014-05-31 -9.72 6.04 2.48
2014-02-28 -6.90 4.17 2.58
2013-11-30 -6.22 3.15 2.98
2013-08-31 -5.12 2.01 3.10
2013-05-31 -5.38 2.20 3.21
2013-02-28 -5.12 2.35 2.77
2012-11-30 -4.95 2.42 2.52
2012-08-31 -4.83 2.54 2.27
2012-05-31 -4.46 2.35 2.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aptose Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aptose Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aptose Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aptose Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aptose Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Aptose Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aptose Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aptose Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aptose Biosciences has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aptose Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Aptose Biosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aptose Biosciences Company Filings, last reported 3 months ago.

DB:LTIA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 14.08 0.00 15.74
2018-09-30 13.93 0.00 15.61
2018-06-30 16.89 0.00 18.46
2018-03-31 14.47 0.00 16.18
2017-12-31 10.20 0.00 11.43
2017-09-30 9.80 0.00 10.87
2017-06-30 10.29 0.00 10.90
2017-03-31 7.76 0.00 8.97
2016-12-31 7.33 0.00 7.94
2016-09-30 6.91 0.00 7.88
2016-06-30 9.04 0.00 9.70
2016-03-31 11.07 0.00 11.59
2016-01-01 13.65 0.00 14.27
2015-09-30 16.90 0.00 17.43
2014-12-31 25.28 0.35 26.38
2014-05-31 26.19 0.49 27.98
2014-02-28 3.65 1.40 6.52
2013-11-30 -1.50 1.43 1.64
2013-08-31 -1.63 0.80 0.57
2013-05-31 -0.76 0.00 0.63
2013-02-28 0.39 0.00 1.51
2012-11-30 1.64 0.00 2.83
2012-08-31 3.15 0.00 4.20
2012-05-31 -1.96 0.87 0.31
  • Aptose Biosciences has no debt.
  • Aptose Biosciences has no debt compared to 5 years ago when it was 424.6%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aptose Biosciences has less than a year of cash runway based on current free cash flow.
  • Aptose Biosciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 23.5% each year.
X
Financial health checks
We assess Aptose Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aptose Biosciences has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Aptose Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aptose Biosciences dividends.
If you bought €2,000 of Aptose Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aptose Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aptose Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:LTIA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:LTIA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aptose Biosciences has not reported any payouts.
  • Unable to verify if Aptose Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aptose Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aptose Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Aptose Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aptose Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aptose Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Aptose Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
William Rice
COMPENSATION $2,499,486
AGE 59
TENURE AS CEO 5.5 years
CEO Bio

Dr. William G. Rice, Ph.D., has been the Chief Executive Officer of Aptose Biosciences Inc. since October 28, 2013 and has been its President since April 10, 2014. Dr. Rice serves as the President and Chief Executive Officer of Cylene Pharmaceutics Inc. since October 2003. He founded Achillion Pharmaceuticals, Inc. and served as its President, Chief Executive Officer and Chief Scientific Officer. He held a faculty position in Pediatric Hematology and Oncology at Emory University School of Medicine, where he first built a program to identify new molecular structures as antiviral and anti-tumor targets. He served as the Senior Scientist and Head of the Laboratory of Antiviral Drug Mechanisms and Manager of the HIV Clinical Interface Laboratory for the National Cancer Institute (NCI), National Institutes of Health (NIH) at the Frederick Cancer Research and Development Center. He also assembled and directed the activities of a series of NCI Intramural Projects: HIV Nucleocapsid Drug Development, ZInc. Finger Inhibitor Screening, Topical Application as Preventive Agents and Application and Development of Computational Tools for Drug Discovery. He served as the NCI's Project Officer for extramural subcontracts aimed at the discovery of topical microbicides and HIV-1 reverse transcriptase inhibitors. He has been the Chairman at Aptose Biosciences Inc. since October 28, 2013. He serves as the Chairman of the Board at Cylene Pharmaceuticals, Inc. since 2003. He has been an Independent Director of Oncolytics Biotech Inc. since June 08, 2015. He has been a Director at Aptose Biosciences Inc. since October 28, 2013. He serves as a Director of Cylene Pharmaceuticals, Inc. since October 2003. He served as a Director of Achillion Pharmaceuticals, Inc. He has pursued drug discovery in a number of therapeutic areas, including anti-tumor, anti-inflammatory and anti-HIV. He has publications from such efforts in the most respected peer-reviewed scientific journals such as Science, Nature, Nature Medicine, Proceedings of the National Academy of Sciences and others. Dr. Rice holds a Ph.D. in Biochemistry from Emory University School of Medicine and was a Post-Doctoral Trainee in the Department of Internal Medicine at the University of Michigan Medical Center.

CEO Compensation
  • William's compensation has increased whilst company is loss making.
  • William's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Aptose Biosciences management team in years:

5.3
Average Tenure
64.5
Average Age
  • The average tenure for the Aptose Biosciences management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

William Rice

TITLE
Chairman
COMPENSATION
$2M
AGE
59
TENURE
5.5 yrs

Greg Chow

TITLE
Senior VP & CFO
COMPENSATION
$2M
AGE
45
TENURE
5.3 yrs

Ernest Kitt

TITLE
Vice President of Development & Technical Operations
COMPENSATION
$389K
TENURE
3.1 yrs

Dan Von Hoff

TITLE
Senior VP of Medical Affairs
AGE
70
TENURE
5.5 yrs

Steve Howell

TITLE
Chief Medical Officer
AGE
73
TENURE
4.6 yrs
Board of Directors Tenure

Average tenure and age of the Aptose Biosciences board of directors in years:

4.9
Average Tenure
65
Average Age
  • The tenure for the Aptose Biosciences board of directors is about average.
Board of Directors

Dan Von Hoff

TITLE
Senior VP of Medical Affairs
AGE
70

Mark Vincent

TITLE
Director
COMPENSATION
$174K
AGE
65
TENURE
11.6 yrs

William Rice

TITLE
Chairman
COMPENSATION
$2M
AGE
59
TENURE
5.5 yrs

Denis Burger

TITLE
Lead Director
COMPENSATION
$222K
AGE
74

Warren Whitehead

TITLE
Director
COMPENSATION
$174K
AGE
66
TENURE
8 yrs

Brian Druker

TITLE
Chairman of Scientific Advisory Board
AGE
62
TENURE
5.5 yrs

Erich Platzer

TITLE
Director
COMPENSATION
$170K
AGE
68
TENURE
4.3 yrs

Michael Andreeff

TITLE
Member of Scientific Advisory Board
TENURE
4.1 yrs

Caroline Loewy

TITLE
Director
COMPENSATION
$99K
AGE
51
TENURE
1 yrs

Carol Ashe

TITLE
Director
COMPENSATION
$83K
AGE
60
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Aptose Biosciences insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
19. Apr 19 Buy William Rice Individual 18. Apr 19 18. Apr 19 10,000 €1.65 €16,464
21. Mar 19 Buy Erich Platzer Individual 19. Mar 19 19. Mar 19 20,000 €1.93 €38,592
15. Mar 19 Buy William Rice Individual 14. Mar 19 14. Mar 19 10,000 €1.68 €16,805
14. Mar 19 Buy Gregory Chow Individual 13. Mar 19 13. Mar 19 15,000 €1.58 €23,284
09. Oct 18 Buy William Rice Individual 08. Oct 18 08. Oct 18 10,000 €1.85 €18,519
16. Jul 18 Buy Gregory Chow Individual 16. Jul 18 16. Jul 18 6,000 €2.63 €15,750
16. Jul 18 Buy William Rice Individual 16. Jul 18 16. Jul 18 10,000 €2.66 €26,563
X
Management checks
We assess Aptose Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aptose Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase Ib clinical trial for the treatment of patients with relapsed/refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a bioavailable non-covalent small molecule that is in Phase I clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia and various B-cell malignancies. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581 for the treatment of hematologic malignancies, as well as related molecules. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.

Details
Name: Aptose Biosciences Inc.
LTIA
Exchange: DB
Founded: 1986
CA$65,482,958
40,249,112
Website: http://www.aptose.com
Address: Aptose Biosciences Inc.
251 Consumers Road,
Suite 1105,
Toronto,
Ontario, M2J 4R3,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX APS Common Shares The Toronto Stock Exchange CA CAD 11. Jul 2007
NasdaqCM APTO Common Shares Nasdaq Capital Market US USD 11. Jul 2007
DB LTIA Common Shares Deutsche Boerse AG DE EUR 11. Jul 2007
LSE 0UI8 Common Shares London Stock Exchange GB CAD 11. Jul 2007
Number of employees
Current staff
Staff numbers
23
Aptose Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 21:39
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/03/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.